Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guerbet SA

Latest From Proacta Inc.

US green light for clinical testing of Proacta's reversible MKI inhibitor

The US FDA has given Proacta the go-ahead to begin clinical trials of PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.

Cancer New Zealand

Yakult option puts LivTech on track for cancer antibody deal

Following a setback earlier this year, the privately held Japanese bioventure LivTech has bounced back with a new deal for one of its main streams of research, signing an option agreement with Yakult Honsha for a series of novel anticancer antibodies.

Cancer Japan

Deals Shaping the Medical Industry (09/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Yakult extends Proacta alliance to another anticancer prodrug

Japan's Yakult Honsha has expanded a collaborative R&D and commercialisation agreement with Proacta to include another of the private US firm's hypoxia-activated prodrugs for cancer.

Cancer New Zealand
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Guerbet SA
  • Senior Management
  • Yves L'Epine, CEO
    Jean-Francois Le Martret, CFO
  • Contact Info
  • Guerbet SA
    Phone: (33) 1 45 91 50 00
    Rue des Vanesses, 15
    P.O. Box 50400 Villepinte, 93420